Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Active, not recruiting · NCT01937117 · Registry updated 2026-08-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-08-13 | NCT01937117 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
| Translational Breast Cancer Research Consortium | 19 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine | Houston | United States | 306 |
| Fred Hutchinson Cancer Research Center - University of Washington | Seattle | United States | 1 |
| Indiana University Simon Cancer Center | Indianapolis | United States | 9 |
| Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital | Washington D.C. | United States | 1 |
| Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 15 |
| Mayo Clinic | Rochester | United States | 664 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | United States | 3 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| University of Alabama Comprehensive Cancer Center | Birmingham | United States | 3 |
| Vanderbilt University | Nashville | United States | 51 |